NKTR-255 + CD19 CAR-T cell therapy

This drug is a combination of **NKTR-255**, a polymer-conjugated interleukin-15 (IL-15) receptor agonist, and **CD19 chimeric antigen receptor (CAR) T cell therapy**, designed to improve outcomes for patients with relapsed or refractory B-cell malignancies—particularly large B-cell lymphoma (LBCL) and acute lymphoblastic leukemia (B-ALL)[1][2][4][5]. NKTR-255 stimulates, proliferates, and expands natural killer (NK) and CD8+ T-cells, including CAR-T cells, by agonizing the IL-15 receptor, leading to enhanced anti-tumor activity and improved CAR-T cell persistence and trafficking[1][2][4]. Clinical and preclinical studies show that this combination significantly increases the rate and durability of complete remissions compared to CD19 CAR-T cell therapy alone, with a favorable safety profile[1][2][4][5].